CN113740538A - Method and product for detecting SARS-CoV-2 novel coronavirus IgM/IgG antibody - Google Patents
Method and product for detecting SARS-CoV-2 novel coronavirus IgM/IgG antibody Download PDFInfo
- Publication number
- CN113740538A CN113740538A CN202010463796.XA CN202010463796A CN113740538A CN 113740538 A CN113740538 A CN 113740538A CN 202010463796 A CN202010463796 A CN 202010463796A CN 113740538 A CN113740538 A CN 113740538A
- Authority
- CN
- China
- Prior art keywords
- cov
- sars
- detection
- antibody
- igm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 69
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 35
- 238000001514 detection method Methods 0.000 claims abstract description 89
- 239000004005 microsphere Substances 0.000 claims abstract description 45
- 238000003908 quality control method Methods 0.000 claims abstract description 29
- 101710141454 Nucleoprotein Proteins 0.000 claims abstract description 25
- 210000002966 serum Anatomy 0.000 claims abstract description 16
- 102000036639 antigens Human genes 0.000 claims abstract description 15
- 108091007433 antigens Proteins 0.000 claims abstract description 15
- 239000000427 antigen Substances 0.000 claims abstract description 14
- 238000005516 engineering process Methods 0.000 claims abstract description 14
- 238000003745 diagnosis Methods 0.000 claims abstract description 13
- 210000004369 blood Anatomy 0.000 claims abstract description 12
- 239000008280 blood Substances 0.000 claims abstract description 12
- 241000283707 Capra Species 0.000 claims abstract description 7
- 241000287828 Gallus gallus Species 0.000 claims abstract description 7
- 239000011248 coating agent Substances 0.000 claims abstract description 7
- 238000000576 coating method Methods 0.000 claims abstract description 7
- 238000012360 testing method Methods 0.000 claims description 28
- 239000012528 membrane Substances 0.000 claims description 12
- 230000001681 protective effect Effects 0.000 claims description 10
- 239000000020 Nitrocellulose Substances 0.000 claims description 9
- 229920001220 nitrocellulos Polymers 0.000 claims description 9
- 238000009007 Diagnostic Kit Methods 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000002250 absorbent Substances 0.000 claims description 5
- 230000002745 absorbent Effects 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 claims description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 230000005284 excitation Effects 0.000 claims description 2
- 230000009871 nonspecific binding Effects 0.000 claims description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims 3
- 229910052761 rare earth metal Inorganic materials 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000009210 therapy by ultrasound Methods 0.000 claims 1
- 238000003317 immunochromatography Methods 0.000 abstract description 12
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract description 4
- 239000000523 sample Substances 0.000 description 24
- 239000007788 liquid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108700002099 Coronavirus Nucleocapsid Proteins Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000003365 glass fiber Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention belongs to the field of biotechnology, and relates to a method and a product for detecting SARS-CoV-2 novel coronavirus IgM and IgG antibodies based on a fluorescence immunochromatography technology. The process of the invention is a one-step process comprising: loading the recombinant N protein antigen of SARS-CoV-2 marked by fluorescent microsphere on a carrier; coating rat anti-human IgM/IgG antibody on a detection carrier connected with the microsphere labeled antigen carrier as a detection line; the chicken IgY marked by the fluorescent microspheres correspondingly coats goat anti-chicken IgY antibodies as quality control lines; dropping human plasma, serum or whole blood sample on the carrier of fluorescent microsphere labeled antigen, if the sample contains SARS-CoV-2 coronavirus antibody, a detection line can be formed on the detection carrier, and the quality control line is positive; and if only the quality control line is displayed and the detection line is not displayed, the result is negative. The invention solves the problem of clinical rapid diagnosis of SARS-CoV-2 coronavirus infection, and has the characteristics of high detection sensitivity, strong specificity, high accuracy, simple and rapid operation, and selectable instrument reading judgment.
Description
Technical Field
The invention belongs to the field of biotechnology, relates to a method for detecting SRS-CoV-2 novel coronavirus antibodies in serum (plasma), and particularly relates to a method and a product for detecting SARS-CoV-2 novel coronavirus IgM and IgG antibodies based on a fluorescence immunochromatography technology.
Background
The novel coronavirus pneumonia caused by SARS-CoV-2 coronavirus is acute respiratory infectious disease, mainly manifested by fever, debilitation and dry cough, and clinically shows hypoxia-hypoxia state and dyspnea, and severe patients rapidly progress to acute respiratory distress syndrome, sepsis shock, metabolic acidosis difficult to correct and blood coagulation dysfunction. To reduce the impact and harm of new coronavirus infections on public health, those skilled in the art are working on research and development including mechanisms, diagnostics, pharmacotherapy and vaccine prevention. Wherein, the timely discovery of new coronavirus patients is the key to control the disease transmission and reduce the fatality rate of the diseases, and the establishment of a rapid and sensitive diagnosis technology has great significance.
Because the detection of antigen is limited by the screening of specific antibody and the dependence on P3 laboratory, the current rapid diagnosis method for the novel coronavirus pneumonia mainly comprises two methods: (1) fluorescent real-time quantitative PCR technology based on virus nucleic acid detection, etc.; (2) antibody detection based on ELISA and immunofluorescence techniques; practice shows that compared with nucleic acid detection, immunoassay can effectively avoid the problems of low detection rate and the like caused by a sampling mode and poor RNA nucleic acid stability; research shows that the N protein is the most stable and abundant structural protein in the SARS-CoV-2 novel coronavirus, is an ideal antigen for antibody diagnosis, and is favorable for realizing sensitive and accurate detection. At present, a kit for detecting a novel coronavirus antibody is rarely seen, and the detection rate, the detection time, the operation difficulty and the like in the prior art are urgently needed to be improved.
The fluorescence immunochromatography technology is an improved technology based on the traditional immunochromatography technology, has the advantages of high specificity, simple operation, short detection time and the like, and also has the advantages of high sensitivity and accurate quantification.
Based on the current situation of the prior art, the inventor of the application intends to provide a method for detecting SRS-CoV-2 novel coronavirus antibodies in serum (plasma), in particular to a method and a product for detecting SARS-CoV-2 novel coronavirus IgM and IgG antibodies based on a fluorescence immunochromatography technology.
Disclosure of Invention
The invention aims to provide a method for detecting SRS-CoV-2 novel coronavirus antibodies in serum (plasma) based on the current situation of the prior art, in particular to a method and a product for detecting SARS-CoV-2 novel coronavirus IgM and IgG antibodies based on a fluorescence immunochromatography technology.
The invention provides a semi-quantitative detection method of specific IgM/IgG antibody of SARS-CoV-2 novel coronavirus N protein antigen in serum and plasma based on fluorescence immunochromatographic assay technology, wherein the SARS-CoV-2 novel coronavirus N protein for antibody capture is recombinant SARS-CoV-2 novel coronavirus N protein purified by affinity column;
the method is a one-step detection method, has the characteristics of high detection sensitivity, strong specificity, high accuracy and simple and quick operation, and is suitable for various field occasions such as clinical detection, intensive care unit, bedside detection, field quarantine, epidemiological screening and the like.
The invention comprises the following steps: n protein antigen of SARS-CoV-2 loaded on the carrier as fluorescent microsphere mark; the N protein antigen of SARS-CoV-2 on the carrier is the recombinant N protein of SARS-CoV-2, which is characterized in that the protein purified by affinity column, N end has GST label, and the sequence optimized by codon is used for prokaryotic expression, and the sequence is as follows:
“ATGTCTGATAATGGTCCGCAATCAAACCAACGTAGTGCTCCGCGCATTACATTTGGTGGTCCGACAGATTCAACT GACAATAACCAGAATGGTGGTCGCAATGGTGCACGTCCAAAACAGCGCCGTCCGCAAGGTTTACCGAATAATACT GCTTCTTGGTTCACAGCTCTCACTCAGCATGGTAAGGAGGAACTTCGTTTCCCTCGTGGTCAGGGTGTTCCAATCAA CACTAATAGTGGTCCAGATGACCAAATTGGTTACTACCGTCGTGCTACTCGTCGTGTTCGTGGTGGTGACGGTAAA ATGAAAGAGCTCTCTCCGCGTTGGTACTTCTATTACCTGGGTACTGGTCCAGAAGCTTCACTTCCGTACGGTGCTAA CAAAGAAGGTATCGTATGGGTTGCAACTGAGGGTGCTTTGAATACACCGAAAGACCACATTGGTACTCGCAATCC TAATAACAATGCTGCTACTGTTCTGCAACTTCCTCAAGGTACAACATTGCCAAAAGGTTTCTACGCAGAGGGTTCTC GTGGTGGTAGTCAAGCTTCTTCTCGCTCTTCATCACGTAGTCGCGGTAATTCACGTAATTCAACTCCTGGTTCTAGT CGTGGTAATTCTCCTGCTCGTATGGCTTCTGGTGGTGGTGAAACTGCTCTCGCTCTGTTGCTGCTGGACCGTTTGAA CCAGCTTGAGTCTAAAGTTTCTGGTAAAGGTCAACAACAACAAGGTCAAACTGTTACTAAGAAATCTGCTGCTGAG GCATCTAAAAAGCCTCGCCAAAAACGTACTGCTACAAAACAGTACAACGTTACTCAAGCATTTGGTCGTCGTGGTC CAGAACAAACTCAAGGTAATTTCGGTGACCAAGACCTGATCCGTCAAGGTACTGATTACAAACATTGGCCGCAAAT TGCACAATTTGCTCCAAGTGCTTCTGCATTCTTTGGTATGTCACGCATTGGTATGGAAGTTACACCTTCTGGTACAT GGCTGACTTATCATGGTGCTATTAAATTGGATGACAAAGATCCACAATTCAAAGACAACGTTATCCTGCTGAACAA GCACATTGACGCATACAAAACATTCCCACCAACAGAGCCTAAAAAGGACAAAAAGAAAAAGACTGATGAAGCTCA GCCTTTGCCGCAGCGTCAAAAGAAGCAGCCGACTGTTACTCTTCTTCCTGCTGCTGACATGGATGATTTCTCTCGTC AACTTCAAAATTCTATGAGTGGTGCTTCTGCTGATTCAACTCAGGCA”。
the detection method of the invention comprises the following steps:
(1) loading the recombinant N protein of SARS-CoV-2 marked by fluorescent microsphere on a carrier made of glass fiber; coating a detection line formed by rat anti-human IgM/IgG antibodies and a quality control line correspondingly coated with goat anti-chicken IgY antibodies by chicken IgY marked by fluorescent microspheres on a detection carrier which is a nitrocellulose membrane and is connected with a SARS-CoV-2 recombinant N protein carrier marked by the fluorescent microspheres;
(2) dripping 2 mu L of human serum, 2 mu L of plasma or 5 mu L of whole blood on a carrier coated by the recombinant N protein of SARS-CoV-2 marked by fluorescent microspheres, and dripping 80 mu L of PBS diluent; if the serum, plasma or whole blood sample to be detected contains SARS-CoV-2 novel coronavirus N protein specific IgG antibody, an IgG detection line and a quality control line can be formed on the detection carrier at the same time, and the result is IgG positive; if the serum, plasma or whole blood sample to be detected contains a SARS-CoV-2 novel coronavirus N protein specific IgM antibody, an IgM detection line and a quality control line can be simultaneously formed on the detection carrier, and the result is IgM positive; if the serum, the plasma or the whole blood sample to be detected simultaneously contains the specific IgM and IgG antibodies of the novel SARS-CoV-2 coronavirus N protein, an IgM detection line, an IgG detection line and a quality control line can be simultaneously formed on the detection carrier, and the result shows that the IgM and the IgG are simultaneously positive; if only the quality control line exists, the result is negative; and when the quality control line is not displayed, the detection is invalid.
The invention provides a fluorescence immunochromatographic rapid diagnosis kit for SARS-CoV-2 novel coronavirus antibody, which aims at the detection of SARS-CoV-2 novel coronavirus antibody and has the advantages of simple and convenient one-step method operation, short detection time, high sensitivity, strong specificity, high detectable rate, selectable instrument reading judgment and the like.
The invention relates to a fluorescence immunochromatographic rapid diagnosis kit for SARS-CoV-2 novel coronavirus antibody, which comprises an antibody detection test card and PBS sample diluent with pH7.4; the antibody detection test card comprises a test strip and a lining plate made of plastic materials and wrapping the test strip to protect the test strip, wherein the test strip is based on a plastic bottom lining, a sample pad made of glass fiber and a nitrocellulose membrane are attached to the bottom lining, two ends of the nitrocellulose membrane are respectively lapped with a marking pad and absorbent paper, the sample pad is lapped with the marking pad, the nitrocellulose membrane is provided with an IgM/IgG detection line and a quality control line, and the detection line and the quality control line are positioned between the marking pad and the absorbent paper and sequentially comprise the IgM detection line, the IgG detection line and the quality control line; the outer packaging shell comprises a sample adding slot and a result display slot.
The invention further aims to provide a preparation method of a fluorescence immunochromatographic rapid quantitative diagnostic kit for SARS-CoV-2 novel coronavirus antibody, and the method has the advantages of high stability, simplicity and good repeatability.
The preparation method of the fluorescence immunochromatographic rapid quantitative diagnostic kit mainly comprises the following steps: preparing a SARS-CoV-2 recombinant N protein band marked by fluorescent microspheres of the sample adding layer, a detection line for preparing rat anti-human IgM/IgG antibodies of the detection layer, a quality control line for correspondingly coating goat anti-chicken IgY antibodies by chicken IgY marked by the fluorescent microspheres, and then combining a fluorescence immunochromatographic rapid quantitative diagnosis test paper strip of SARS-CoV-2 novel coronavirus antibodies on a protective plastic lining plate.
The preparation method of the recombinant N protein band of SARS-CoV-2 marked by the fluorescent microsphere of the sample adding layer comprises the following steps (the specific concentration and time can be adjusted according to requirements): 3.125X 106Microspheres were activated with 250. mu.L of activation buffer (0.1M NaH)2PO4pH6.2) was washed 2 times, each time followed by 60s of sonication, and the microspheres were activated in 500. mu.L of activation buffer containing 2.5mg of N-hydroxysulfosuccinimide (sulfonHS) and 2.5mg of N- (3-dimethylaminopropyl) -N-Ethylcarbodiimide (EDC) at 20-22 ℃ for 20 min. Washing the active microspheres twice with PBS; coupling was accomplished by addition of 12.5. mu.g of recombinant N protein of SARS-CoV-2, brought to a final volume of 500. mu.L with PBS, and rotary incubated at 20-22 ℃ for 3 h; with 1mL PBS + 0.05% NaN3And 1.0% bovine serum albumin are sequentially washed with the coupling microspheres; blocking the coupled microspheres with 1mL PBS-NB for 30 min to reduce non-specific binding; microspheres were washed twice with PBS-NB and resuspended in PBS-NB to a final concentration of 2.0X 106The recombinant N protein coupled microsphere of SARS-CoV-2.
The test strip and the detection test card are assembled according to the following method:
referring to fig. 2, the test strip and the test card for detecting the novel SARS-CoV-2 coronavirus IgM/IgG antibody based on the fluorescence immunochromatography technique comprise the following contents: the test strip is composed of a sample adding layer 5, a detection layer 7 connected with the sample adding layer 5, a waste liquid water absorbing layer 8 connected with the detection layer 7, a recombinant N protein marked by fluorescent microspheres and chicken IgY 6 marked by fluorescent microspheres fixed on the sample adding layer 5, a rat anti-human IgM antibody detection line 9 fixed on the detection layer 7 and close to one end of the sample adding layer 5, a rat anti-human IgG antibody detection line 10, and a quality control line 11 fixed on the detection layer 7 and close to one end of the waste liquid water absorbing layer 8, wherein the sample adding layer 5 and the detection layer 7 can be composed of cellulose membranes which can be hydrophilic materials such as cellulose acetate membranes, cellulose nitrate membranes, non-woven fabrics, glass fiber aluminum membranes and the like and easy to uniformly distribute proteins, and the waste liquid water absorbing layer 8 can be made of water absorbing materials such as multilayer filter paper; during assembly, the sample adding layer 5, the detection layer 7 and the waste liquid water absorption layer are overlapped by about 5mm to ensure that liquid smoothly enters an adjacent layer from one layer through chromatography, materials of all parts can be assembled in sequence and then cut into strips, the cut test strip comprises the parts, and the cutting specification is 0.4 or 0.5cm wide;
referring to fig. 1 and 2, the upper part of a test strip cut into strips covers the upper half part 1 of a protective lining board, a sample adding layer 5 is correspondingly overlapped with a sample adding hole 2 of the upper half part 1 of the protective lining board, a waste liquid water absorbing layer 8 is correspondingly overlapped with a vent hole 4 of the upper half part 1 of the protective lining board, a rat antihuman IgM antibody detection line 9, a rat antihuman IgG antibody detection line 10 and a quality control line 11 which are fixed on a detection layer 7 are correspondingly overlapped with a result observation hole 3, the rat antihuman IgM antibody detection line 9, the rat antihuman IgG antibody detection line 10 and the quality control line 11 are visible through the hollowed result observation hole 3, and finally, the lower half part 12 of the protective lining board is covered on the lower half part of the test strip, and the lower half part 12 of the protective lining board is fixedly connected with the upper half part 1 of the protective lining board.
The invention provides a method and a product for detecting SARS-CoV-2 novel coronavirus IgM and IgG antibodies based on a fluorescence immunochromatography technology; the method is a one-step detection method, has the characteristics of high detection sensitivity, strong specificity, high accuracy and simple and quick operation, and is suitable for various field occasions such as clinical detection, intensive care unit, bedside detection, field quarantine, epidemic disease screening and the like.
Compared with the prior art, the invention has the obvious advantages that:
1. the invention solves the clinical problem of rapid diagnosis of SARS-CoV-2 coronavirus infection, has 100 percent positive detection rate and high specificity, improves the sensitivity and the accuracy of detection by replacing the traditional nanogold with the fluorescent microspheres, and has simple one-step operation and convenient reading.
2. The fluorescence immunochromatographic rapid quantitative diagnostic kit for the SARS-CoV-2 novel coronavirus antibody has obvious good sensitivity and detection limit and good specificity; the test strip has low manufacturing cost; does not need to contact with pathogen, and has high safety; the detection time is short, and the field test and diagnosis can be completed quickly, conveniently and effectively.
3. The preparation method of the kit is simple, and the kit has good stability and repeatability.
Drawings
Fig. 1 is a schematic view of an appearance structure of an upper surface of an external protection lining plate of a test strip, wherein 1, the upper half part of the protection lining plate, 2, a sample adding hole, 3, a result observation hole, 4 and an air hole are arranged.
Fig. 2 is a schematic diagram of the side structure of the lower surface of the test strip and the external protective lining board, wherein 5, the sample adding layer, 6, the recombinant N protein marked by the fluorescent microsphere and the chicken IgY marked by the fluorescent microsphere, 7, the detection layer, 8, the waste liquid water absorbing layer, 9, the rat anti-human IgM antibody detection line, 10, the rat anti-human IgG antibody detection line, 11, the goat anti-chicken IgY quality control line, 12, and the lower half part of the protective lining board.
Detailed Description
The invention relates to a method for detecting SARS-CoV-2 novel coronavirus IgG/IgM antibody based on fluorescence immunochromatography, a kit thereof and a preparation method of the kit, which are further described by the following specific implementation method, but the invention is not limited by the embodiment in any way.
Example 1
Materials:
1. reagent
(1) PBS buffer (ph 7.4): sterile PBS buffer solution with the components of NaCl 137mmol/L, KCl 2.7mmol/L and Na2HPO4 10mmol/L,KH2PO42 mmol/L. Subpackaging into sterile container with 20mL, storing at room temperature,
(2) buffer solution for coating protein and antibody preparation, etc., with PBS buffer (pH7.4) as in item (1),
(3) washing solutions for post-coating washing are for example PBST: PBS (pH7.4), 0.05% Tween 20,
(4) the diameter of the fluorescent microspheres can be 200nm, and the excitation light wavelength is 365nm and the emission light wavelength is 618 nm.
2. Antigen and antibody
The SARS-CoV-2 new type coronavirus recombinant N protein antigen used in the invention is a recombinant protein with GST label at the N end and prokaryotic expression by using codon optimized sequence, and is purified by affinity column;
the coated antibody used in the invention is a rat IgG anti-human IgM/IgG antibody, and the quality control line is a goat anti-chicken IgY antibody;
and (3) treating the human serum/plasma/whole blood sample solution to be detected:
2 mu L of human serum, 2 mu L of plasma or 5 mu L of whole blood are dripped on a carrier coated by the recombinant N protein of SARS-CoV-2 marked by fluorescent microspheres, and 80 mu L of PBS diluent is dripped.
And (3) judging a detection result:
the invention relates to a method for detecting SARS-CoV-2 novel coronavirus IgM/IgG antibody based on fluorescence immunochromatography technology and a product thereof, which need to be matched with a portable detector for reading fluorescence results:
c is the fluorescence intensity value of the quality control line,
t1 ═ fluorescence intensity value of IgG line
Fluorescence intensity value of T2 ═ IgM line
IgG＝T1/C；IgM＝T2/C；
IgG negative range (0-0.050) positive (>0.050)
IgM negative range (0-0.020) positive (>0.020)
The above-mentioned qualitative determination method, if there is a standard curve or a reference antibody for quantitative determination, can provide a quantitative determination method according to the format, and combine the clinical test results for comprehensive judgment.
Testing and testing of human serum/plasma/whole blood samples:
the method for detecting the SARS-CoV-2 novel coronavirus IgM/IgG antibody based on the fluorescence immunochromatography technology comprises the following operation steps:
1) taking out the test paper, horizontally placing on a table, dropwise adding 2 mu L of serum, 2 mu L of plasma or 5 mu L of whole blood into a sample adding hole, dropwise adding 80 mu L of PBS diluent, horizontally placing and standing for 10 minutes after sample adding; opening a software MD-reader, then opening a main switch behind the instrument, and pressing 'quick test'; entering an interface to be tested;
2) inserting the test card into the detection hole of the instrument with the sample adding hole facing inwards;
3) pressing a reading button to read and record a fluorescence intensity value;
in this embodiment, the method and kit for detecting the novel SARS-CoV-2 coronavirus IgM/IgG antibody based on fluorescence immunochromatography are used to detect an actual serum/plasma/whole blood sample, and the detection results are shown in the following Table 1: wherein, the sample numbers 1-15 represent 15 patients respectively, C represents quality control MFI, IgG represents MFI of IgG, and IgM represents MFI of IgM, and the result shows that the positive coincidence rate of the semi-quantitative detection method for detecting SARS-CoV-2 novel coronavirus IgM/IgG antibody by utilizing the antigen specificity of recombinant N protein is 100%; the result shows that the method of the invention can accurately and sensitively detect the novel SARS-CoV-2 coronavirus IgM/IgG antibody, and provides effective guarantee for the screening and detection of the novel SARS-CoV-2 coronavirus infection.
TABLE 1
Sequence listing
<110> university of Compound Dan
<120> a method and product for detecting SARS-CoV-2 new type coronavirus IgM/IgG antibody
<130> 20200527
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1266
<212> DNA
<213> SARS-CoV-2
<400> 1
atgtctgata atggtccgca atcaaaccaa cgtagtgctc cgcgcattac atttggtggt 60
ccgacagatt caactgacaa taaccagaat ggtggtcgca atggtgcacg tccaaaacag 120
cgccgtccgc aaggtttacc gaataatact gcttcttggt tcacagctct cactcagcat 180
ggtaaggagg aacttcgttt ccctcgtggt cagggtgttc caatcaacac taatagtggt 240
ccagatgacc aaattggtta ctaccgtcgt gctactcgtc gtgttcgtgg tggtgacggt 300
aaaatgaaag agctctctcc gcgttggtac ttctattacc tgggtactgg tccagaagct 360
tcacttccgt acggtgctaa caaagaaggt atcgtatggg ttgcaactga gggtgctttg 420
aatacaccga aagaccacat tggtactcgc aatcctaata acaatgctgc tactgttctg 480
caacttcctc aaggtacaac attgccaaaa ggtttctacg cagagggttc tcgtggtggt 540
agtcaagctt cttctcgctc ttcatcacgt agtcgcggta attcacgtaa ttcaactcct 600
ggttctagtc gtggtaattc tcctgctcgt atggcttctg gtggtggtga aactgctctc 660
gctctgttgc tgctggaccg tttgaaccag cttgagtcta aagtttctgg taaaggtcaa 720
caacaacaag gtcaaactgt tactaagaaa tctgctgctg aggcatctaa aaagcctcgc 780
caaaaacgta ctgctacaaa acagtacaac gttactcaag catttggtcg tcgtggtcca 840
gaacaaactc aaggtaattt cggtgaccaa gacctgatcc gtcaaggtac tgattacaaa 900
cattggccgc aaattgcaca atttgctcca agtgcttctg cattctttgg tatgtcacgc 960
attggtatgg aagttacacc ttctggtaca tggctgactt atcatggtgc tattaaattg 1020
gatgacaaag atccacaatt caaagacaac gttatcctgc tgaacaagca cattgacgca 1080
tacaaaacat tcccaccaac agagcctaaa aaggacaaaa agaaaaagac tgatgaagct 1140
cagcctttgc cgcagcgtca aaagaagcag ccgactgtta ctcttcttcc tgctgctgac 1200
atggatgatt tctctcgtca acttcaaaat tctatgagtg gtgcttctgc tgattcaact 1260
caggca 1266
Claims (10)
1. A method for detecting SARS-CoV-2 novel coronavirus antibody based on fluorescence immunochromatographic assay technology is characterized by comprising the following steps:
1) the recombinant N protein antigen of SARS-CoV-2 marked by fluorescent microsphere is loaded on the carrier; coating rat anti-human IgM/IgG antibody on a detection carrier connected with the carrier of the fluorescent microsphere labeled antibody as a detection line; the chicken IgY marked by the fluorescent microspheres correspondingly coats goat anti-chicken IgY antibodies as quality control lines;
2) dripping serum, plasma or whole blood to be detected on a carrier coated by recombinant N protein of SARS-CoV-2 marked by fluorescent microspheres, and then dripping PBS diluent; if the sample contains SARS-CoV-2 new coronavirus IgG antibody, an IgG detection line can be formed on the detection carrier, and the quality control line is positive; if the sample contains SARS-CoV-2 new type coronavirus IgM antibody, IgM detection line can be formed on the detection carrier, and simultaneously the quality control line is positive; if the sample contains SARS-CoV-2 new type coronavirus IgM and IgG antibody, IgM detection line, IgG detection line and quality control line are formed on the detection carrier as positive; if only the quality control line is displayed and the detection line is not displayed, the result is negative.
2. The method of claim 1, wherein the recombinant N protein antigen of SARS-CoV-2 has a GST tag at its N-terminus and is prokaryotic expressed using a codon-optimized sequence as follows:
“ATGTCTGATAATGGTCCGCAATCAAACCAACGTAGTGCTCCGCGCATTACATTTGGTGGTCCGACAGATTCAACTGACAATAACCAGAATGGTGGTCGCAATGGTGCACGTCCAAAACAGCGCCGTCCGCAAGGTTTACCGAATAATACTGCTTCTTGGTTCACAGCTCTCACTCAGCATGGTAAGGAGGAACTTCGTTTCCCTCGTGGTCAGGGTGTTCCAATCAACACTAATAGTGGTCCAGATGACCAAATTGGTTACTACCGTCGTGCTACTCGTCGTGTTCGTGGTGGTGACGGTAAAATGAAAGAGCTCTCTCCGCGTTGGTACTTCTATTACCTGGGTACTGGTCCAGAAGCTTCACTTCCGTACGGTGCTAACAAAGAAGGTATCGTATGGGTTGCAACTGAGGGTGCTTTGAATACACCGAAAGACCACATTGGTACTCGCAATCCTAATAACAATGCTGCTACTGTTCTGCAACTTCCTCAAGGTACAACATTGCCAAAAGGTTTCTACGCAGAGGGTTCTCGTGGTGGTAGTCAAGCTTCTTCTCGCTCTTCATCACGTAGTCGCGGTAATTCACGTAATTCAACTCCTGGTTCTAGTCGTGGTAATTCTCCTGCTCGTATGGCTTCTGGTGGTGGTGAAACTGCTCTCGCTCTGTTGCTGCTGGACCGTTTGAACCAGCTTGAGTCTAAAGTTTCTGGTAAAGGTCAACAACAACAAGGTCAAACTGTTACTAAGAAATCTGCTGCTGAGGCATCTAAAAAGCCTCGCCAAAAACGTACTGCTACAAAACAGTACAACGTTACTCAAGCATTTGGTCGTCGTGGTCCAGAACAAACTCAAGGTAATTTCGGTGACCAAGACCTGATCCGTCAAGGTACTGATTACAAACATTGGCCGCAAATTGCACAATTTGCTCCAAGTGCTTCTGCATTCTTTGGTATGTCACGCATTGGTATGGAAGTTACACCTTCTGGTACATGGCTGACTTATCATGGTGCTATTAAATTGGATGACAAAGATCCACAATTCAAAGACAACGTTATCCTGCTGAACAAGCACATTGACGCATACAAAACATTCCCACCAACAGAGCCTAAAAAGGACAAAAAGAAAAAGACTGATGAAGCTCAGCCTTTGCCGCAGCGTCAAAAGAAGCAGCCGACTGTTACTCTTCTTCCTGCTGCTGACATGGATGATTTCTCTCGTCAACTTCAAAATTCTATGAGTGGTGCTTCTGCTGATTCAACTCAGGCA”。
3. the method according to claim 1, wherein in step 1), the fluorescent microsphere is made of rare earth element (Eu +).
4. The method of claim 1, wherein in step 2), 2 μ L of serum, 2 μ L of plasma or 5 μ L of whole blood is assayed, and 80 μ L of PBS diluent is added dropwise.
5. A SARS-CoV-2 new type coronavirus antibody rapid diagnosis reagent box is characterized in that a SARS-CoV-2 new type coronavirus antibody detection test paper strip (1) is arranged in the reagent box.
6. The SARS-CoV-2 novel coronavirus antibody rapid diagnostic kit as claimed in claim 5, wherein the SARS-CoV-2 novel coronavirus antibody detection test strip (1) comprises a plastic substrate, a sample pad, a nitrocellulose membrane, a label pad and a water-absorbent paper.
7. The SARS-CoV-2 novel coronavirus antibody rapid diagnosis kit as claimed in claim 5 or 6, which comprises a plastic substrate, and a sample pad and a nitrocellulose membrane arranged on the substrate, wherein the nitrocellulose membrane has two ends respectively lapped with a label pad and absorbent paper, the sample pad is lapped with the label pad, the nitrocellulose membrane is provided with an IgM/IgG detection line and a quality control line, and the detection line and the quality control line are arranged between the label pad and the absorbent paper and are an IgM detection line, an IgG detection line and a quality control line in sequence.
8. The method for preparing the SARS-CoV-2 coronavirus antibody rapid diagnostic kit as claimed in claim 7, which mainly comprises: preparing a SARS-CoV-2 recombinant N protein band marked by fluorescent microspheres of the sample adding layer, a detection line for preparing rat anti-human IgM/IgG antibodies of the detection layer, a quality control line for correspondingly coating goat anti-chicken IgY antibodies by chicken IgY marked by the fluorescent microspheres, and then combining a fluorescence immunochromatographic rapid quantitative diagnosis test paper strip of SARS-CoV-2 novel coronavirus antibodies on a protective plastic lining plate.
9. The method for preparing the SARS-CoV-2 coronavirus antibody rapid diagnostic kit as claimed in claim 8, wherein the recombinant N protein band of SARS-CoV-2 marked by the fluorescent microsphere of the sample addition layer is prepared by the following steps: washing the microspheres with an activation buffer solution for 2 times, performing ultrasonic treatment for 60s after each washing, activating the microspheres in the activation buffer solution containing N-hydroxysulfosuccinimide and N- (3-dimethylaminopropyl) -N-ethylcarbodiimide at 20-22 ℃, and washing the activated microspheres with PBS for two times; coupling was accomplished by addition of recombinant N protein of SARS-CoV-2, and final body was made with PBSRotating and culturing at 20-22 deg.C for 3 hr until the volume reaches 500 μ L; with 1mL PBS + 0.05% NaN3And 1.0% bovine serum albumin are sequentially washed with the coupling microspheres; blocking the coupled microspheres with 1mL PBS-NB for 30 min to reduce non-specific binding; microspheres were washed twice with PBS-NB and resuspended in PBS-NB to a final concentration of 2.0X 106The recombinant N protein coupled microsphere of SARS-CoV-2.
10. The method for preparing the SARS-CoV-2 coronavirus antibody rapid diagnosis kit as claimed in claim 9, wherein the recombinant N protein of SARS-CoV-2 marked by the fluorescent microsphere of the sample addition layer is an antigen marked by the immunofluorescent microsphere made of rare earth element (Eu +) and is a recombinant N protein antigen of SARS-CoV-2, the fluorescence excitation wavelength of the immunofluorescent microsphere is 365nm, and the emission wavelength is 618 nm. The size of the microspheres was 200 nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010463796.XA CN113740538A (en) | 2020-05-27 | 2020-05-27 | Method and product for detecting SARS-CoV-2 novel coronavirus IgM/IgG antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010463796.XA CN113740538A (en) | 2020-05-27 | 2020-05-27 | Method and product for detecting SARS-CoV-2 novel coronavirus IgM/IgG antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113740538A true CN113740538A (en) | 2021-12-03 |
Family
ID=78723889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010463796.XA Pending CN113740538A (en) | 2020-05-27 | 2020-05-27 | Method and product for detecting SARS-CoV-2 novel coronavirus IgM/IgG antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113740538A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115541875A (en) * | 2022-09-27 | 2022-12-30 | 江苏迅睿生物技术有限公司 | N gene detection primer and probe group, chromatography test strip, preparation method, detection kit and detection method |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004245896A1 (en) * | 2003-06-10 | 2004-12-16 | Agency For Science, Technology And Research | Method of diagnosing SARS corona virus infection |
| CN1570638A (en) * | 2003-07-22 | 2005-01-26 | 李克生 | SARS virus antibody detecting method, rapid diagnosis kit and preparation method |
| CN1661372A (en) * | 2004-02-25 | 2005-08-31 | 中国科学院动物研究所 | Immunization microsphere in use for detecting SARS antibody, preparation method and application |
| CN1690711A (en) * | 2004-04-23 | 2005-11-02 | 中国人民解放军军事医学科学院微生物流行病研究所 | Immune chromatographic test paper bar based on up conversion luminescence technology |
| US20080199851A1 (en) * | 2006-02-21 | 2008-08-21 | Richard Laswell Egan | Methods and compositions for analyte detection |
| WO2017039967A1 (en) * | 2015-09-01 | 2017-03-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method and device for detecting antigen-specific antibodies in a biological fluid sample by using neodymium magnets |
| CN108318685A (en) * | 2018-05-04 | 2018-07-24 | 广州敏捷生物技术有限公司 | Immunofluorescence for detecting canine coronavirus antigen chromatographs detection card and preparation method |
| CN111024954A (en) * | 2020-03-09 | 2020-04-17 | 深圳市易瑞生物技术股份有限公司 | Colloidal gold immunochromatography device for combined detection of COVID-19 antigen and antibody and use method thereof |
| CN111153991A (en) * | 2020-02-26 | 2020-05-15 | 北京博奥森生物技术有限公司 | Human SARS-CoV-2 monoclonal antibody and its preparation method and use |
-
2020
- 2020-05-27 CN CN202010463796.XA patent/CN113740538A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004245896A1 (en) * | 2003-06-10 | 2004-12-16 | Agency For Science, Technology And Research | Method of diagnosing SARS corona virus infection |
| CN1570638A (en) * | 2003-07-22 | 2005-01-26 | 李克生 | SARS virus antibody detecting method, rapid diagnosis kit and preparation method |
| CN1661372A (en) * | 2004-02-25 | 2005-08-31 | 中国科学院动物研究所 | Immunization microsphere in use for detecting SARS antibody, preparation method and application |
| CN1690711A (en) * | 2004-04-23 | 2005-11-02 | 中国人民解放军军事医学科学院微生物流行病研究所 | Immune chromatographic test paper bar based on up conversion luminescence technology |
| US20080199851A1 (en) * | 2006-02-21 | 2008-08-21 | Richard Laswell Egan | Methods and compositions for analyte detection |
| WO2017039967A1 (en) * | 2015-09-01 | 2017-03-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method and device for detecting antigen-specific antibodies in a biological fluid sample by using neodymium magnets |
| CN108318685A (en) * | 2018-05-04 | 2018-07-24 | 广州敏捷生物技术有限公司 | Immunofluorescence for detecting canine coronavirus antigen chromatographs detection card and preparation method |
| CN111153991A (en) * | 2020-02-26 | 2020-05-15 | 北京博奥森生物技术有限公司 | Human SARS-CoV-2 monoclonal antibody and its preparation method and use |
| CN111024954A (en) * | 2020-03-09 | 2020-04-17 | 深圳市易瑞生物技术股份有限公司 | Colloidal gold immunochromatography device for combined detection of COVID-19 antigen and antibody and use method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 聂聪;侯宝翠;王静;杨宇;: "荧光免疫层析技术检测寨卡病毒IgG抗体", 中华卫生杀虫药械, no. 02 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115541875A (en) * | 2022-09-27 | 2022-12-30 | 江苏迅睿生物技术有限公司 | N gene detection primer and probe group, chromatography test strip, preparation method, detection kit and detection method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111337689A (en) | Novel coronavirus detection kit | |
| CN109765384B (en) | Canine coronavirus antibody fluorescence detection test strip and preparation method and application thereof | |
| EP2853894B1 (en) | Diagnostic kits and immunoassay methods for diagnosis and differentiation of African Swine Fever Virus (ASFV) and Classical Swine Fever Virus (CSFV) | |
| CN111303297B (en) | Recombinant protein for detecting 2019 novel coronavirus antibody by double-antigen sandwich method, test strip, preparation method and application | |
| CN111233985A (en) | Preparation method of novel coronavirus IgA antibody rapid detection test strip | |
| US7785773B1 (en) | Method of diagnosis and kit therefor | |
| CN111378018B (en) | Test strip for detecting novel coronavirus antibody and preparation method and application thereof | |
| WO2022206401A1 (en) | Detection method and detection kit for high-sensitivity sars-cov-2 neutralizing antibody | |
| CN113295865B (en) | Immunochromatographic device for detecting SARS-CoV-2 virus neutralizing antibody and its use | |
| CN105277693B (en) | Human parainfluenza virus quantum dot immunochromatography typing detection card, preparation method and applications | |
| CN105859843A (en) | Preparation method of respiratory syncytial virus antigen and rapid respiratory syncytial virus antibody detection kit prepared from antigen | |
| CN111007257A (en) | Porcine pseudorabies virus gE protein antibody detection immune blocking chromatography kit and application thereof | |
| EP1328811B1 (en) | Hcv mosaic antigen composition | |
| CN111435136A (en) | Time-resolved fluorescence immunochromatography kit for detecting novel coronavirus and preparation method thereof | |
| CN110568177B (en) | Zika virus E antigen and application thereof in fluorescence immunochromatography reagent | |
| CN112946294A (en) | Novel coronavirus 2019-nCoV antibody detection test strip and preparation method and application thereof | |
| CN113740538A (en) | Method and product for detecting SARS-CoV-2 novel coronavirus IgM/IgG antibody | |
| CN106188248A (en) | A kind of Epstein-Barr virus antigen preparation procedure and utilize the quick detection kit of detection Epstein-Barr virus antibody prepared by this antigen | |
| CN110954695B (en) | Norovirus GI and GII type quantum dot joint inspection test strip and preparation method and application thereof | |
| CN112379089A (en) | New coronavirus detection method based on quantum dot microsphere immunochromatographic test strip | |
| CN111624336A (en) | Novel coronavirus IgG/IgM antibody detection kit and application method thereof | |
| CN109633163B (en) | procalcitonin/C reactive protein two-in-one detection kit | |
| CN112334478A (en) | Antibody pairs for rapid influenza a diagnostic tests | |
| JP3841559B2 (en) | Immunological examination method and immunological examination kit | |
| CN111812335B (en) | Method for maintaining antigen activity in antigen-fluorescent microsphere conjugate and application of method in chromatography detection reagent of novel coronavirus antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |